REGULATORY
Annual Savings from Use of Biosimilars Stands at Just 8.7 Billion Yen: MHLW
The use of generic drugs reduced the annual medical expenditure by 1,299.1 billion yen, but biosimilars accounted for just 8.7 billion yen of this figure, the Ministry of Health, Labor and Welfare (MHLW) announced on March 5. The MHLW estimated…
To read the full story
Related Article
REGULATORY
- DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





